1
   
                                  SCHEDULE 14A
                                 (RULE 14A-101)
 
                    INFORMATION REQUIRED IN PROXY STATEMENT
 
                            SCHEDULE 14A INFORMATION
          PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
                    EXCHANGE ACT OF 1934 (AMENDMENT NO.   )
 
Filed by the Registrant [X]
 
Filed by a Party other than the Registrant [ ]
 
Check the appropriate box:
 
                                             
 [ ]  Preliminary Proxy Statement               [ ]  Confidential, for Use of the Commission
                                                      Only (as permitted by Rule 14a-6(e)(2))
 [ ]  Definitive Proxy Statement
 [X]  Definitive Additional Materials
 [ ]  Soliciting Material Pursuant to 
       Rule 14a-11(c) or Rule 14a-12



                        HEALTHDYNE TECHNOLOGIES, INC.
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified In Its Charter)


- --------------------------------------------------------------------------------
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check the appropriate box):
 
[X]  No fee required.
 
[ ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 
     (1)  Title of each class of securities to which transaction applies:
 
     (2)  Aggregate number of securities to which transaction applies:
 
     (3)  Per unit price or other underlying value of transaction computed
          pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
          filing fee is calculated and state how it was determined):
 
     (4)  Proposed maximum aggregate value of transaction:
 
     (5)  Total fee paid:
 
[ ]  Fee paid previously with preliminary materials:
 
[ ]  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.
 
     (1)  Amount Previously Paid:
 
     (2)  Form, Schedule or Registration Statement No.:
 
     (3)  Filing Party:
 
     (4)  Date Filed:
    
   2

   
HEALTHDYNE TECHNOLOGIES                                        M. Wayne Boylston
STATES INVACARE'S PRESS                                        July 24, 1997
RELEASE INACCURATE                                             (770)499-1212


FOR IMMEDIATE RELEASE

        Marietta, Georgia, July 24, 1997 Healthdyne Technologies, Inc.
(Nasdaq:HDTC) said Invacare Corporation mischaracterized the bylaw amendment
Healthdyne's Board will adopt effective October 31, 1997, if the Board's 
nominees are reelected.  Contrary to Invacare's statements in its press release
yesterday, Healthdyne will repeal the existing bylaw procedures relating to
special shareholders meetings, as well as reduce from 60% to 25% the percentage
of holders of the Company's outstanding shares which would be necessary to call
special meetings.  This was clearly stated in the letter Healthdyne
Technologies sent to shareholders yesterday.  The public statements made by A.
Malachi Mixon, III, Chairman of Invacare Corporation, yesterday inaccurately
alleged that the Company's bylaw amendment would not repeal the existing special
meeting procedures.
        Parker H. Petit, Chairman of the Board, in commenting on Mr. Mixon's
other statements, said: "Mr. Mixon's threat to sell some or all of Invacare's
position in Healthdyne Technologies stock appears to be an attempt to push the
market price down closer to Invacare's grossly inadequate $15 offer.  This is
further evidence that he is going to continue to act in Invacare's interest, not
in the best interest of our shareholders."
        "We flatly reject Mr. Mixon's criticism of our proposed amendment to our
Shareholder Rights Plan," Mr. Petit continued.  "We designed that amendment to
encourage a bidder to pay a high price for the Company because that is the best
interest of shareholders."

    

   3

   

        Healthdyne Technologies designs, manufactures and markets
technologically advanced medical devices for use in the home, as well as other
specialized clinical settings.  The Company's products include diagnostic and
therapeutic devices for the evaluation and treatment of sleep disorders,
non-invasive ventilators, oxygen concentrators and medication nebulizers for
the treatment of respiratory disorders, monitors for infants at risk for SIDS,
and products for asthma management.